Treatment innovation for patients: a collaborative network in the Benelux and an inside view of 20 years of Galapagos

• Published in: Acta clinica belgica (English ed. Online) Vol. 77; no. 1; pp. 233 - 240
• Main Authors: Durez, Patrick, Hoekema, André, Huizinga, Tom, Gazin, Muriel, Present, Erik, Veelaert, Dirk, Wigerinck, Piet, Westhovens, René
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 01.02.2022
• Subjects: collaboration; Delivery of Health Care; Humans; Innovation; research and development; triple helix; research and development; Innovation; triple helix; collaboration
• ISSN: 1784-3286; 2295-3337
• DOI: 10.1080/17843286.2020.1812830

A better understanding of disease pathology, improvements in relevant disease outcomes, better treatment strategies and the development of novel therapies all contribute to improving healthcare and treatment options. However, the global drug development model today is under increasing pressure, with very high drug development costs. Collaborative research is critical for bringing together different capabilities and expertise to increase the success of drug development, and large-scale collaborations with multiple partners are becoming increasingly common. Research clusters supported by local governments play an important role in bringing together academic centres, hospitals, scientists, and pharmaceutical and biotechnology industries. The 'triple helix' model, with academia, industry and governments working together, has been an important factor in the successful development of novel therapies. During the past 20 years, Galapagos has worked closely with academic centres, hospitals, governments and pharmaceutical companies to conduct innovative research and to develop a novel therapy for rheumatoid arthritis. These collaborations have brought unique knowledge, expertise and skills together, as well as crucial funding at various stages. Local governments in the Benelux have operated in this triple helix model to provide the necessary environment and to stimulate companies to achieve innovation through collaboration. Although the triple helix has already proved successful, evolution to a quadruple helix that includes patients and patient representatives could be the next step to ensure innovation remains transformational.